Cheryl Barton is director of PharmaVision, 

Articles

Competition in the organ-on-a-chip market increases as NETRI enters the arena.

Frontrunner in Organ-on-a-Chip

This specific guidance refers to a DCT as a clinical trial where some or all the trial-related activities occur at locations other than traditional clinical trial sites.



FDA Gives Guidance for Decentralized Clinical Trials for Drugs, Devices

The new research and development capacities set the stage for completion of product development for LEON’s manufacturing devices and will be used to showcase the devices and provide process development services to clients using LEON’s equipment.

LEON Sets Lab Facilities at IZB in Munich

The acquisition was completed through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio.

Sanofi Acquires Provention Bio 

Feliza Mirasol is the science editor for 

INTERPHEX was back in full swing with Keynote sessions highlighting cutting-edge technologies that are setting the stage for the bio/pharma industry’s future.

Springing Forward

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Strike action is impacting numerous sectors across Europe, including the bio/pharma industry.

On Strike!

Mike Hennessy Jr. is the Chairman and CEO of 

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Young Pups and Leopards

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA is encouraging sponsors to conduct studies and file applications for full approval of products authorized by Emergency Use Authorizations.

FDA and Industry Prepare for End to COVID-19 Emergency

The event, cosponsored by FDA and USP, hosted regulators and industry leaders to discuss the challenges in strengthening the medical product supply chain.

Collaboration Key at the APEC Medical Product Supply Chain Dialogue Event 

clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.

News